Global Cystic Fibrosis Therapeutics Market Outlook 2022
The Global Cystic Fibrosis Therapeutics industry has reported a tremendous growth in the recent years, and is presenting ample opportunities to the industry players. With improving life expectancy and rising awareness, the global cystic fibrosis therapeutics market is poised to scale newer acmes. Also, there lies enormous opportunity for industry participants to tap the fast growing market, which would garner huge revenue on the back of rising strategic consolidations and commercialization of the new drugs targeting the CFTR gene or protein.
The latest research by RNCOS titled, "Global Cystic Fibrosis Therapeutics Market Outlook 2022”, unfolds the market dynamics of the cystic fibrosis therapeutics market. According to this new research report, the market for cystic fibrosis therapeutics was valued at US$ 1.94 Billion in 2016.
The report showcases the segmentation of cystic fibrosis therapeutics market on the basis of the pharmacological class, mutation class, drug molecule type, and geographical penetration. It also provides an insight on the current market scenario, as well as forecasts of the aforementioned segments till 2022. The report provides an in-depth analysis of all the major segments, taking into account the major developments taking place at global level in the respective segments that will further boost the growth of cystic fibrosis therapeutics market.
Based on pharmacological class, the report broadly categorizes cystic fibrosis therapeutics market into Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Mucolytic agents, Pancreatic Enzymes products, Antibiotics, and Other therapies. CFTR modulators emerged as the major revenue earners of the industry, holding the largest share. This large share of the market is attributed to recent market approvals of Kalydeco (ivacaftor) and Orkambi (lumacaftor and ivacaftor) for the treatment of patients with CF and robust pipeline.
Based on CF mutation class, the cystic fibrosis therapeutics market is further categorized into commercialized and non-commercialized mutation class specific therapies. CFTR mutation Class II accounted for largest share in the total cystic fibrosis therapeutics market in 2016.
Based on drug molecule type, the cystic fibrosis therapeutics market is further categorized into small molecule and biologic. The small molecule segment accounted for largest share in the total cystic fibrosis therapeutics market in 2016.
Additionally, the report covers the geographic analysis of the global cystic fibrosis therapeutics market by segmenting into three major geographic regions - North America, Europe, and Asia Pacific. North America is the largest market for cystic fibrosis. This high share is attributed to increasing awareness in the market, coupled with growing research initiatives. However, the European market is poised to witness the highest growth owing to increasing focus of players in this region.
Besides, the report covers the profiles of key players like Genentech, Inc. (A Member of the Roche Group), Novartis, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Gilead Sciences, Inc., Allergan plc, etc. with the key financials, providing a comprehensive outlook of global cystic fibrosis therapeutics industry. In addition, the report elucidates key developments of players related to cystic fibrosis industry. Overall, the report provides all the pre-requisite information for clients looking to venture in this industry, and facilitate them to formulate schemes while going for an investment/partnership in the industry.
The latest research by RNCOS titled, "Global Cystic Fibrosis Therapeutics Market Outlook 2022”, unfolds the market dynamics of the cystic fibrosis therapeutics market. According to this new research report, the market for cystic fibrosis therapeutics was valued at US$ 1.94 Billion in 2016.
The report showcases the segmentation of cystic fibrosis therapeutics market on the basis of the pharmacological class, mutation class, drug molecule type, and geographical penetration. It also provides an insight on the current market scenario, as well as forecasts of the aforementioned segments till 2022. The report provides an in-depth analysis of all the major segments, taking into account the major developments taking place at global level in the respective segments that will further boost the growth of cystic fibrosis therapeutics market.
Based on pharmacological class, the report broadly categorizes cystic fibrosis therapeutics market into Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Mucolytic agents, Pancreatic Enzymes products, Antibiotics, and Other therapies. CFTR modulators emerged as the major revenue earners of the industry, holding the largest share. This large share of the market is attributed to recent market approvals of Kalydeco (ivacaftor) and Orkambi (lumacaftor and ivacaftor) for the treatment of patients with CF and robust pipeline.
Based on CF mutation class, the cystic fibrosis therapeutics market is further categorized into commercialized and non-commercialized mutation class specific therapies. CFTR mutation Class II accounted for largest share in the total cystic fibrosis therapeutics market in 2016.
Based on drug molecule type, the cystic fibrosis therapeutics market is further categorized into small molecule and biologic. The small molecule segment accounted for largest share in the total cystic fibrosis therapeutics market in 2016.
Additionally, the report covers the geographic analysis of the global cystic fibrosis therapeutics market by segmenting into three major geographic regions - North America, Europe, and Asia Pacific. North America is the largest market for cystic fibrosis. This high share is attributed to increasing awareness in the market, coupled with growing research initiatives. However, the European market is poised to witness the highest growth owing to increasing focus of players in this region.
Besides, the report covers the profiles of key players like Genentech, Inc. (A Member of the Roche Group), Novartis, Vertex Pharmaceuticals Incorporated, Abbott Laboratories, Gilead Sciences, Inc., Allergan plc, etc. with the key financials, providing a comprehensive outlook of global cystic fibrosis therapeutics industry. In addition, the report elucidates key developments of players related to cystic fibrosis industry. Overall, the report provides all the pre-requisite information for clients looking to venture in this industry, and facilitate them to formulate schemes while going for an investment/partnership in the industry.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. CYSTIC FIBROSIS: AN OVERVIEW
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Robust Pipeline
4.1.2 Rising Prevalence of Cystic Fibrosis
4.1.3 Rising Life expectancy of Cystic Fibrosis Patient’s
4.1.4 Improvement in Diagnostic Technologies
4.1.5 Increasing Awareness
4.1.6 Unmet Medical Needs
4.2 Restraints
4.2.1 Cystic Fibrosis Related Complications
4.2.2 Increased Risk of Bacterial Infections in Cystic Fibrosis Patients
4.2.3 High Cost
4.3 Opportunities
4.3.1 Patent Expiry of Biggest-Selling Drugs
4.3.2 Gene Therapy Breakthrough for Cystic Fibrosis
5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET OUTLOOK 2022
6. MAJOR MARKETED PRODUCTS
6.1 Orkambi (lumacaftor/ivacaftor)
6.2 Kalydeco (Ivacaftor)
6.3 Cayston (Inhaled Aztreonam)
6.4 Pulmozyme (Dornase Alfa)
6.5 TOBI
6.6 Creon
6.7 Zenpep
6.8 Ventolin
6.9 Bronchitol (Inhaled Mannitol)
6.10 ADEKplusTM
6.11 Ibuprofen
7. MARKET SEGMENTATION BY PHARMACOLOGICAL CLASS
7.1 CFTR modulators
7.2 Mucolytic Agents
7.3 Pancreatic Enzyme Replacement Products
7.4 Antibiotics
7.5 Other Therapies
8. MARKET SEGMENTATION BY DRUG MOLECULE
8.1 Small Molecule
8.2 Biologic Drugs
9. MARKET SEGMENTATION BY CYSTIC FIBROSIS MUTATION TYPE
9.1 Commercialized
9.1.1 Class I
9.1.2 Class II
9.1.3 Class III
9.2 Non-Commercialized
9.2.1 Class IV
9.2.2 Class V
9.2.3 Class VI
10. MARKET SEGMENTATION BY GEOGRAPHY
10.1 North America
10.2 Europe
10.3 Asia Pacific
11. INDUSTRY TRENDS & DEVELOPMENTS
11.1 Genetic Testing
11.2 Technological Advances
11.3 CFTR Modulators - Gaining Momentum
11.4 Upsurge in the Number of Strategic Alliances
11.5 Combination Therapy
11.6 Co-pay and Assistance Programs by Vendors
11.7 Increased R&D Activities: Pillars for Market Growth
12. CYSTIC FIBROSIS PIPELINE ANALYSIS
12.1 Pipeline Analysis by Phase of Development
12.2 Pipeline Analysis by Key Players
12.3 Pipeline Analysis by Geography
12.4 Pipeline Analysis by Routes of Administration
13. PORTER'S FIVE FORCES ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1 Share of Major Players
15. COMPANY PROFILES
15.1 Genentech, Inc. (A Member of the Roche Group)
15.2 Novartis
15.3 Vertex Pharmaceuticals Incorporated
15.4 Abbott Laboratories
15.5 Gilead Sciences, Inc.
15.6 Johnson & Johnson
15.7 Allergan plc
15.8 GlaxoSmithKline
15.9 Mylan N.V.
15.10 Pharmaxis Ltd
2. RESEARCH METHODOLOGY
3. CYSTIC FIBROSIS: AN OVERVIEW
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Robust Pipeline
4.1.2 Rising Prevalence of Cystic Fibrosis
4.1.3 Rising Life expectancy of Cystic Fibrosis Patient’s
4.1.4 Improvement in Diagnostic Technologies
4.1.5 Increasing Awareness
4.1.6 Unmet Medical Needs
4.2 Restraints
4.2.1 Cystic Fibrosis Related Complications
4.2.2 Increased Risk of Bacterial Infections in Cystic Fibrosis Patients
4.2.3 High Cost
4.3 Opportunities
4.3.1 Patent Expiry of Biggest-Selling Drugs
4.3.2 Gene Therapy Breakthrough for Cystic Fibrosis
5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET OUTLOOK 2022
6. MAJOR MARKETED PRODUCTS
6.1 Orkambi (lumacaftor/ivacaftor)
6.2 Kalydeco (Ivacaftor)
6.3 Cayston (Inhaled Aztreonam)
6.4 Pulmozyme (Dornase Alfa)
6.5 TOBI
6.6 Creon
6.7 Zenpep
6.8 Ventolin
6.9 Bronchitol (Inhaled Mannitol)
6.10 ADEKplusTM
6.11 Ibuprofen
7. MARKET SEGMENTATION BY PHARMACOLOGICAL CLASS
7.1 CFTR modulators
7.2 Mucolytic Agents
7.3 Pancreatic Enzyme Replacement Products
7.4 Antibiotics
7.5 Other Therapies
8. MARKET SEGMENTATION BY DRUG MOLECULE
8.1 Small Molecule
8.2 Biologic Drugs
9. MARKET SEGMENTATION BY CYSTIC FIBROSIS MUTATION TYPE
9.1 Commercialized
9.1.1 Class I
9.1.2 Class II
9.1.3 Class III
9.2 Non-Commercialized
9.2.1 Class IV
9.2.2 Class V
9.2.3 Class VI
10. MARKET SEGMENTATION BY GEOGRAPHY
10.1 North America
10.2 Europe
10.3 Asia Pacific
11. INDUSTRY TRENDS & DEVELOPMENTS
11.1 Genetic Testing
11.2 Technological Advances
11.3 CFTR Modulators - Gaining Momentum
11.4 Upsurge in the Number of Strategic Alliances
11.5 Combination Therapy
11.6 Co-pay and Assistance Programs by Vendors
11.7 Increased R&D Activities: Pillars for Market Growth
12. CYSTIC FIBROSIS PIPELINE ANALYSIS
12.1 Pipeline Analysis by Phase of Development
12.2 Pipeline Analysis by Key Players
12.3 Pipeline Analysis by Geography
12.4 Pipeline Analysis by Routes of Administration
13. PORTER'S FIVE FORCES ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1 Share of Major Players
15. COMPANY PROFILES
15.1 Genentech, Inc. (A Member of the Roche Group)
15.2 Novartis
15.3 Vertex Pharmaceuticals Incorporated
15.4 Abbott Laboratories
15.5 Gilead Sciences, Inc.
15.6 Johnson & Johnson
15.7 Allergan plc
15.8 GlaxoSmithKline
15.9 Mylan N.V.
15.10 Pharmaxis Ltd
LIST OF FIGURES:
Figure 4-1: %age of CF individuals over the age of
Figure 4-2: Estimated Prevalence of Cystic Fibrosis per 100,000 Habitants, 2015-2016
Figure 4-3: Effect of novel therapies on life expectancy of cystic fibrosis patients
Figure 5-1: Global – Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 6-1: Global - Sales of Orkambi (Million US$), 2015 & 2016
Figure 6-2: Global - Sales of Kalydeco (Million US$), 2012-2016
Figure 6-3: Global - Sales of Cayston (Million US$), 2014-2016
Figure 6-4: Global - Sales of Pulmozyme (Million US$), 2012-2016
Figure 6-5: Global - Sales of TOBI (Million US$), 2014-2016
Figure 6-6: Global - Sales of Creon (Million US$), 2014-2016
Figure 6-7: Global - Sales of Zenpep (Million US$), 2014-2016
Figure 6-8: Global - Sales of Ventolin (Million US$), 2014-2016
Figure 6-9: Global - Sales of Bronchitol (Million US$), 2014-2016
Figure 7-1: Global – Cystic Fibrosis Therapeutics Market Breakup by Pharmacological Class (%), 2016
Figure 7-2: Global - CFTR Modulator Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-3: Global - Mucolytic Agents Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-4: Global - Pancreatic Enzyme Replacement Products Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-5: Global – Antibiotics Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-6: Global – Other Therapies Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 8-1: Global – Cystic Fibrosis Therapeutics Market by Drug Molecule Type (%), 2016
Figure 8-2: Global - Small Molecule Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 8-3: Global - Biologic Drugs Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-1: Global - Cystic Fibrosis Therapeutics Market Breakup by CF Mutation Type (%), 2016
Figure 9-2: Global – Class I Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-3: Prevalence of the F508del Mutation in Patients with Cystic Fibrosis (% of Patients with at Least 1 Allele)
Figure 9-4: Global – Class II Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-5: Global – Class III Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 10-1: Global - Cystic Fibrosis Therapeutics Market Breakup by Geography (%), 2016
Figure 10-2: North America - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 10-3: Europe - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 10-4: Asia-Pacific – Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 12-1: Global - Cystic Fibrosis Clinical Trials by Phase till June, 2017
Figure 12-2: Global - Cystic Fibrosis Clinical Trials by Key Players till June, 2017
Figure 12-3: Global – Cystic Fibrosis Clinical Trials by Countries till June, 2017
Figure 12-4: Global – Cystic Fibrosis Clinical Trials by Route of Administration till June, 2017
Figure 14-1: Global - Share of Major Players in Cystic Fibrosis Therapeutics Market (%), 2016
Figure 15-1: F. Hoffman La Roche Ltd. - Breakup of Revenue by Business Segments (%), 2016
Figure 15-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Segments (%), 2016
Figure 15-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Geography (%), 2016
Figure 15-4: Novartis - Sales by Business Segments (%), 2016
Figure 15-5: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
Figure 15-6: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 15-7: Novartis - Sales by Geography (%), 2016
Figure 15-8: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Product (%), 2016
Figure 15-9: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Geography (%), 2016
Figure 15-10: Abbott Laboratories – Net Sales Breakup by Business Segments (%), 2016
Figure 15-11: Abbott Laboratories – Net Sales Breakup by Geography (%), 2016
Figure 15-12: Gilead Sciences, Inc. - Breakup of Revenue by Geographic Segments (%), 2016
Figure 15-13: Johnson & Johnson - Sales by Business Segments (%), 2016
Figure 15-14: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
Figure 15-15: Johnson & Johnson - Sales by Geography (%), 2016
Figure 15-16: Allergan plc - Breakup of Revenue by Business Segments (%), 2016
Figure 15-17: Allergan plc - Breakup of Revenue by Geography (%), 2016
Figure 15-18: GlaxoSmithKline plc - Breakup of Revenue by Business Segments (%), 2016
Figure 15-19: GlaxoSmithKline plc - Pharmaceuticals Division Revenue by Segments (%), 2016
Figure 15-20: GlaxoSmithKline plc - Breakup of Revenue by Geography (%), 2016
Figure 15-21: Mylan N.V. - Breakup of Revenue by Geographic Region (%), 2016
Figure 15-22: Pharmaxis Ltd - Breakup of Revenue by Business Segment (%), 2016
Figure 4-1: %age of CF individuals over the age of
Figure 4-2: Estimated Prevalence of Cystic Fibrosis per 100,000 Habitants, 2015-2016
Figure 4-3: Effect of novel therapies on life expectancy of cystic fibrosis patients
Figure 5-1: Global – Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 6-1: Global - Sales of Orkambi (Million US$), 2015 & 2016
Figure 6-2: Global - Sales of Kalydeco (Million US$), 2012-2016
Figure 6-3: Global - Sales of Cayston (Million US$), 2014-2016
Figure 6-4: Global - Sales of Pulmozyme (Million US$), 2012-2016
Figure 6-5: Global - Sales of TOBI (Million US$), 2014-2016
Figure 6-6: Global - Sales of Creon (Million US$), 2014-2016
Figure 6-7: Global - Sales of Zenpep (Million US$), 2014-2016
Figure 6-8: Global - Sales of Ventolin (Million US$), 2014-2016
Figure 6-9: Global - Sales of Bronchitol (Million US$), 2014-2016
Figure 7-1: Global – Cystic Fibrosis Therapeutics Market Breakup by Pharmacological Class (%), 2016
Figure 7-2: Global - CFTR Modulator Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-3: Global - Mucolytic Agents Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-4: Global - Pancreatic Enzyme Replacement Products Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-5: Global – Antibiotics Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 7-6: Global – Other Therapies Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 8-1: Global – Cystic Fibrosis Therapeutics Market by Drug Molecule Type (%), 2016
Figure 8-2: Global - Small Molecule Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 8-3: Global - Biologic Drugs Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-1: Global - Cystic Fibrosis Therapeutics Market Breakup by CF Mutation Type (%), 2016
Figure 9-2: Global – Class I Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-3: Prevalence of the F508del Mutation in Patients with Cystic Fibrosis (% of Patients with at Least 1 Allele)
Figure 9-4: Global – Class II Gene Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 9-5: Global – Class III Mutation Specific Therapy Market for Cystic Fibrosis (Billion US$), 2016-2022
Figure 10-1: Global - Cystic Fibrosis Therapeutics Market Breakup by Geography (%), 2016
Figure 10-2: North America - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 10-3: Europe - Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 10-4: Asia-Pacific – Cystic Fibrosis Therapeutics Market (Billion US$), 2016-2022
Figure 12-1: Global - Cystic Fibrosis Clinical Trials by Phase till June, 2017
Figure 12-2: Global - Cystic Fibrosis Clinical Trials by Key Players till June, 2017
Figure 12-3: Global – Cystic Fibrosis Clinical Trials by Countries till June, 2017
Figure 12-4: Global – Cystic Fibrosis Clinical Trials by Route of Administration till June, 2017
Figure 14-1: Global - Share of Major Players in Cystic Fibrosis Therapeutics Market (%), 2016
Figure 15-1: F. Hoffman La Roche Ltd. - Breakup of Revenue by Business Segments (%), 2016
Figure 15-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Segments (%), 2016
Figure 15-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Revenue by Geography (%), 2016
Figure 15-4: Novartis - Sales by Business Segments (%), 2016
Figure 15-5: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
Figure 15-6: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 15-7: Novartis - Sales by Geography (%), 2016
Figure 15-8: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Product (%), 2016
Figure 15-9: Vertex Pharmaceuticals Incorporated – Breakup of Revenue by Geography (%), 2016
Figure 15-10: Abbott Laboratories – Net Sales Breakup by Business Segments (%), 2016
Figure 15-11: Abbott Laboratories – Net Sales Breakup by Geography (%), 2016
Figure 15-12: Gilead Sciences, Inc. - Breakup of Revenue by Geographic Segments (%), 2016
Figure 15-13: Johnson & Johnson - Sales by Business Segments (%), 2016
Figure 15-14: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
Figure 15-15: Johnson & Johnson - Sales by Geography (%), 2016
Figure 15-16: Allergan plc - Breakup of Revenue by Business Segments (%), 2016
Figure 15-17: Allergan plc - Breakup of Revenue by Geography (%), 2016
Figure 15-18: GlaxoSmithKline plc - Breakup of Revenue by Business Segments (%), 2016
Figure 15-19: GlaxoSmithKline plc - Pharmaceuticals Division Revenue by Segments (%), 2016
Figure 15-20: GlaxoSmithKline plc - Breakup of Revenue by Geography (%), 2016
Figure 15-21: Mylan N.V. - Breakup of Revenue by Geographic Region (%), 2016
Figure 15-22: Pharmaxis Ltd - Breakup of Revenue by Business Segment (%), 2016
LIST OF TABLES:
Table 4 -1: Global - Key Cystic Fibrosis Drugs and Patent Expiry Status
Table 12-1: Global – Cystic Fibrosis Products Pipeline Analysis
Table 14-1: Global - Major Cystic Fibrosis Drugs
Table 15-1: F. Hoffman La Roche Ltd. - Key Financials (Billion US$), 2014-2016
Table 15-2: Genentech, Inc. - Commercialized Cystic Fibrosis Product
Table 15-3: Genentech, Inc. - Cystic Fibrosis Drugs in Pipeline
Table 15-4: Novartis – Key Financials (Billion US$), 2014-2016
Table 15-5: Novartis - Commercialized Cystic Fibrosis Product
Table 15-6: Novartis - Cystic Fibrosis Drugs in Pipeline
Table 15-7: Vertex Pharmaceuticals Incorporated – Key Financials (Million US$), 2014-2016
Table 15-8: Vertex Pharmaceuticals Incorporated - Commercialized Cystic Fibrosis Product
Table 15-9: Vertex Pharmaceuticals Incorporated - Cystic Fibrosis Drugs in Pipeline
Table 15-10: Abbott Laboratories – Key Financials (Million US$), 2014-2016
Table 15-11: Abbott Laboratories - Commercialized Cystic Fibrosis Product
Table 15-12: Gilead Sciences, Inc. - Key Financials (Billion US$), 2014-2016
Table 15-13: Gilead Sciences, Inc. - Commercialized Cystic Fibrosis Product
Table 15-14: Gilead Sciences, Inc. – Cystic Fibrosis Drugs in Pipeline
Table 15-15: Johnson & Johnson – Key Financials (Billion US$), 2014-2016
Table 15-16: Johnson & Johnson - Commercialized Cystic Fibrosis Product
Table 15-17: Allergan plc - Key Financials (Million US$), 2014-2016
Table 15-18: Allergan plc - Commercialized Cystic Fibrosis Product
Table 15-19: GlaxoSmithKline plc - Key Financials (Million US$), 2014-2016
Table 15-20: GlaxoSmithKline plc - Commercialized Cystic Fibrosis Product
Table 15-21: GlaxoSmithKline plc – Cystic Fibrosis Drugs in Pipeline
Table 15-22: Mylan N.V. - Key Financials (Million US$), 2014-2016
Table 15-23: Mylan N.V. - Commercialized Cystic Fibrosis Product
Table 15-24: Pharmaxis Ltd - Key Financials (Million US$), 2014-2016
Table 15-25: Pharmaxis Ltd - Commercialized Cystic Fibrosis Product
Table 15-26: Pharmaxis Ltd – Cystic Fibrosis Drugs in Pipeline
Table 4 -1: Global - Key Cystic Fibrosis Drugs and Patent Expiry Status
Table 12-1: Global – Cystic Fibrosis Products Pipeline Analysis
Table 14-1: Global - Major Cystic Fibrosis Drugs
Table 15-1: F. Hoffman La Roche Ltd. - Key Financials (Billion US$), 2014-2016
Table 15-2: Genentech, Inc. - Commercialized Cystic Fibrosis Product
Table 15-3: Genentech, Inc. - Cystic Fibrosis Drugs in Pipeline
Table 15-4: Novartis – Key Financials (Billion US$), 2014-2016
Table 15-5: Novartis - Commercialized Cystic Fibrosis Product
Table 15-6: Novartis - Cystic Fibrosis Drugs in Pipeline
Table 15-7: Vertex Pharmaceuticals Incorporated – Key Financials (Million US$), 2014-2016
Table 15-8: Vertex Pharmaceuticals Incorporated - Commercialized Cystic Fibrosis Product
Table 15-9: Vertex Pharmaceuticals Incorporated - Cystic Fibrosis Drugs in Pipeline
Table 15-10: Abbott Laboratories – Key Financials (Million US$), 2014-2016
Table 15-11: Abbott Laboratories - Commercialized Cystic Fibrosis Product
Table 15-12: Gilead Sciences, Inc. - Key Financials (Billion US$), 2014-2016
Table 15-13: Gilead Sciences, Inc. - Commercialized Cystic Fibrosis Product
Table 15-14: Gilead Sciences, Inc. – Cystic Fibrosis Drugs in Pipeline
Table 15-15: Johnson & Johnson – Key Financials (Billion US$), 2014-2016
Table 15-16: Johnson & Johnson - Commercialized Cystic Fibrosis Product
Table 15-17: Allergan plc - Key Financials (Million US$), 2014-2016
Table 15-18: Allergan plc - Commercialized Cystic Fibrosis Product
Table 15-19: GlaxoSmithKline plc - Key Financials (Million US$), 2014-2016
Table 15-20: GlaxoSmithKline plc - Commercialized Cystic Fibrosis Product
Table 15-21: GlaxoSmithKline plc – Cystic Fibrosis Drugs in Pipeline
Table 15-22: Mylan N.V. - Key Financials (Million US$), 2014-2016
Table 15-23: Mylan N.V. - Commercialized Cystic Fibrosis Product
Table 15-24: Pharmaxis Ltd - Key Financials (Million US$), 2014-2016
Table 15-25: Pharmaxis Ltd - Commercialized Cystic Fibrosis Product
Table 15-26: Pharmaxis Ltd – Cystic Fibrosis Drugs in Pipeline
